Association between reactive cutaneous capillary endothelial proliferation and the efficacy of camrelizumab in esophageal cancer: a retrospective cohort study

作者：Yuzi Qiu, Guobin Su, Lan Zhang, Haiyan Fan, Huijin Zhao, Chunyan Wang, Lulu Liu, Bo Chen, Xiaoming Li, Shengmian Li · 发表于：Journal of Thoracic Disease · 年份：2025 · DOI：10.21037/jtd-2025-366 · 被引用次数：5 · 研究领域：Esophageal Cancer Research and Treatment、Cancer Immunotherapy and Biomarkers、Systemic Sclerosis and Related Diseases

Background: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a common immune-related adverse event (irAE) related to camrelizumab. This study sought to investigate the relationship between RCCEP and the treatment efficacy of camrelizumab in esophageal cancer (EC), and to explore the risk factors for RCCEP. Methods: This retrospective study collected the data of patients with EC who were treated with camrelizumab between November 2019 and November 2023. The patients were divided into RCCEP-negative groups and RCCEP-positive groups based on the occurrence of RCCEP. Subsequently, the Chi-squared test was applied to analyze the differences in objective response rate (ORR) and disease control rate (DCR) between the two groups. The association between progression-free survival (PFS) or overall survival (OS), and RCCEP was analyzed by the log-rank test. The factors associated with RCCEP were analyzed using univariable and multivariable Logistic regression analyses. Data cutoff was on February 2, 2024. Results: 72.49%, P<0.001). In the multivariate Cox analysis, RCCEP was found to be independently associated with longer PFS (P<0.001) and OS (P<0.001). In the univariate Cox analysis of patients with RCCEP, neither RCCEP time nor grade was associated with prolonged PFS and OS. The multivariable logistic regression analysis revealed that more camrelizumab treatment cycles was significantly associated with a higher risk of RCCEP [odds ratio (OR) =1.24; 95% confidence int...